# Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

> **NCT02905006** · PHASE2 · COMPLETED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 250 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Bimekizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02905006
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-06
- **Final completion:** 2017-07
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2022-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02905006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02905006, "Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02905006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*